EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Titan Pharmaceuticals's enterprise value is $0.10 Mil.
Titan Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Titan Pharmaceuticals's EV-to-Revenue for today is 96.00.
The historical rank and industry rank for Titan Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
TTNP'
s EV-to-Revenue Range Over the Past 10 Years
Min: -2164.52 Med: 5.52 Max: 829.24
Current: 96
During the past 13 years, the highest EV-to-Revenue of Titan Pharmaceuticals was 829.24. The lowest was -2164.52. And the median was 5.52.
TTNP's EV-to-Revenue is ranked worse than 83.95% of 1034
companies
in the Biotechnology industry
Industry Median: 8.205
vs TTNP: 96.00
Titan Pharmaceuticals EV-to-Revenue Historical Data
The historical data trend for Titan Pharmaceuticals's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Titan Pharmaceuticals's EV-to-Revenue
For the Biotechnology subindustry, Titan Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Titan Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Titan Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Titan Pharmaceuticals's EV-to-Revenue falls into.
Titan Pharmaceuticals's current Enterprise Value is $0.10 Mil.
Titan Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Titan Pharmaceuticals's share price for today is $6.845.
Titan Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Titan Pharmaceuticals EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Titan Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Titan Pharmaceuticals (Titan Pharmaceuticals) Business Description
Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TTNP has been successfully added to your 